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Bovine tuberculosis (BtB) caused by Mycobacterium bovis remains a major problem in both the 
developed and developing countries. control of BtB in the UK is carried out by test and slaughter of 
infected animals, based primarily on the tuberculin skin test (ppD). Vaccination with the attenuated 
strain of the M. bovis pathogen, BcG, is not used to control bovine tuberculosis in cattle at present, 
due to its variable efficacy and because it interferes with the PPD test. Diagnostic tests capable of 
Differentiating Infected from Vaccinated Animals (DIVA) have been developed that detect immune 
responses to M. bovis antigens absent in BCG; but these are too expensive and insufficiently sensitive 
to be used for BtB control worldwide. to address these problems we aimed to generate a synergistic 
vaccine and diagnostic approach that would permit the vaccination of cattle without interfering with 
the conventional ppD-based surveillance. the approach was to widen the pool of M. bovis antigens 
that could be used as DiVA targets, by identifying antigenic proteins that could be deleted from BcG 
without affecting the persistence and protective efficacy of the vaccine in cattle. Using transposon 
mutagenesis we identified genes that were essential and those that were non-essential for persistence 
in bovine lymph nodes. We then inactivated selected immunogenic, but non-essential genes in BcG 
Danish to create a diagnostic-compatible triple knock-out ΔBCG TK strain. The protective efficacy of 
the ΔBcG tK was tested in guinea pigs experimentally infected with M. bovis by aerosol and found 
to be equivalent to wild-type BcG. A complementary diagnostic skin test was developed with the 
antigenic proteins encoded by the deleted genes which did not cross-react in vaccinated or in uninfected 
guinea pigs. this study demonstrates the functionality of a new and improved BcG strain which 
retains its protective efficacy but is diagnostically compatible with a novel DIVA skin test that could be 
implemented in control programmes.
Bovine TB (BTB) is one of the most complex animal health problems that the world’s cattle industry faces today 
and which causes significant economic losses1,2. BTB also causes zoonotic TB, prompting, in 2017, the first road 
map to combat zoonotic TB to be rolled out3–5. The active surveillance and control of BTB in most parts of the 
world depends on animal screening by tuberculin skin testing and the removal of test-positive animals by cull-
ing6. The tuberculin skin test is performed by injection of small quantities of M. bovis purified protein deriva-
tive (PPD-B), which is a crude and complex antigenic mixture that provokes a visible immune reaction on the 
skin7. To mitigate cross-reactivity with environmental mycobacteria and to optimise specificity, in the so-called 
comparative tuberculin test, PPD-B is sometimes supplemented by injection of PPD derived from the related 
Mycobacterium avium (PPD-A). Many countries also use the so-called single intradermal test relying only on the 
injection of PPD-B, a test format optimised for sensitivity, also often used as international trade test. Tuberculin 
skin testing is compulsory in many countries. Yet control by test-and-cull is expensive and societally and/or 
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economically unacceptable in many countries. It also fails to achieve TB eradication in some epidemiological 
circumstances8.
Vaccination is nearly always the most cost-effective means to control infectious disease. The BCG vaccine was 
developed for control of human tuberculosis by Albert Calmette and Camille Guerin by repeated sub-culturing of 
the bovine TB bacillus, Mycobacterium bovis until it lost virulence for guinea pigs yet protected them from chal-
lenge with live virulent TB bacilli. The BCG vaccine was first used in humans in 1921 and has since become the 
most widely used vaccine for humans9. Experimental approaches to developing an improved vaccine against TB 
have included the use of attenuated mycobacteria, subunit vaccines, and DNA vaccines10,11. Several live attenuated 
mycobacterial vaccines have shown promising efficacy against M. tuberculosis challenge in animal models11–15 and 
have progressed to clinical trials16,17. There is also evidence that deletion of genes from BCG can result in unal-
tered or even superior protective efficacy compared to the corresponding parental BCG18. BCG is also effective in 
protecting cattle against TB and has been shown to be capable of reducing the number, duration and severity of 
herd breakdowns19–22. However, it is not used to control BTB since BCG shares many antigens with M. bovis23,24 
resulting in the failure of the PPD skin test to distinguish between a BCG-vaccinated and BTB-infected cow25.
The discovery that the development of BCG from M. bovis involved the concomitant deletion of large regions 
of the BCG chromosome (the RD regions)26,27 stimulated the search for antigens that have been lost in the BCG 
genome and may therefore be used in a novel test capable of Differentiating Infected from Vaccinated Animals 
(DIVA). Antigens such as ESAT-6 and CFP10, both encoded on the RD1 region have been used as DIVA anti-
gens28,29 in humans and cattle blood tests (interferon-gamma release assays, IGRA)28–30. However, a drawback 
of the IGRA tests is that they are laboratory-based requiring blood samples to be taken from infected animals, 
transported to the laboratory within a tight timeline and under temperature-controlled transport conditions. The 
test result must then be reported back to the field. These requirements make the IGRA DIVA tests expensive and 
inappropriate for developing countries with limited resources and technological infrastructure31. In contrast, a 
DIVA skin test would overcome these limitations28.
Recently a defined diagnostic skin test was developed based on a cocktail of DIVA antigens, ESAT-6, CFP-10 
and Rv3615c, that allow the differential diagnosis of M. bovis-infected from BCG-vaccinated animals29,32,33. The 
specificity of this DIVA test is high but its sensitivity is less than the SIT test32,34,35. Although adding additional M. 
bovis antigens to the cocktail would likely increase its sensitivity, this is not a viable option since no other potential 
DIVA antigens have been identified within the RD regions of BCG; and adding non-DIVA M. bovis antigens to 
the cocktail will likely decrease the specificity of the test.
Our aim was to develop a new BCG vaccine that is compatible with a sensitive and affordable DIVA skin 
test. The approach we used is based on the observation that at least three M. bovis antigens (ESAT-6, CFP-10 
and Rv3615c) are dispensable for the protective efficacy of BCG. This led us to hypothesize that the programme 
of accidental deletion of antigens from M. bovis initiated by Calmette and Guerin to develop the BCG vaccine, 
could be continued by rational design. We therefore initiated a project to construct a novel strain of BCG, ΔBCG, 
deleted in additional antigens dispensable for protection. Vaccination with ΔBCG would thereby provide us with 
the opportunity of adding additional antigens, deleted from the ΔBCG genome, to the current DIVA cocktail that 
might provide an enhanced sensitivity skin test reagent capable of detecting BTB infection in ΔBCG inoculated 
animals.
It is well established that persistence of BCG in the host is crucial for its protective efficacy36. In a previous 
paper we describe the development of a high throughput transposon mutagenesis approach that was used to iden-
tify BCG genes that influence the ability of the vaccine to persist in the bovine host37. In this paper we describe 
the use of that dataset to identify BCG genes encoding antigens that do not impair the ability of BCG to persist 
in the bovine host and are therefore candidate genes that could be deleted. We go on to describe the construction 
of a ΔBCG antigen-depleted strain that it is safe and induces protective immunity comparable to wild-type BCG 
against M. bovis infection in guinea pigs. In parallel we also describe the development of a skin test diagnostic 
based on detection of antigens deleted from the ΔBCG strain. This study provides a novel approach to develop-
ment of rationally-designed live vaccines.
Results
The starting point for our experiments was the identification of genes that influence the survival of BCG in the 
bovine lymph node. The details of these experiments are fully described elsewhere37, with the method based on 
the original BCG lymph node challenge model38. Briefly, a BCG Danish transposon (Tn) library was constructed 
and inoculated into the prescapular lymph nodes of three calves. The library was recovered from lymph nodes 
after 3 weeks and the input and output library pools were compared by Tn-seq and TRANSIT’s Resampling 
method analysis39 to identify genes that, when inactivated by the transposon, influenced persistence in bovine 
lymph nodes40. Genes that did not influence persistence were deemed dispensable and were therefore considered 
candidate for deletion in the engineered ΔBCG strain. Genes in the list of dispensable loci that encoded antigens 
were identified by cross-checking against a list of 500 proteins whose immunoreactivity in TB-infected cows has 
been already characterized41,42 to identify dispensable antigenic proteins.
Five genes encoding antigens were identified as Tn mutants in the library whose fold changes during in vivo 
passage in cattle was between 0.5 to 2-fold (Fig. 1a), indicating that they were not essential for persistence in 
the bovine lymph condition, and so could be eliminated from the genome via three genome deletions with-
out compromising the ability to persist in cattle. The genes selected were BCG3043, BCG2897, BCG2895, 
BCG3679 and BCG3680 which are orthologs of M.tb genes Rv3020c, MPT70, MPT83, Rv3615c and Rv3616c, 
respectively. Rv3020c is a member of the ESX family of virulence factors known to induce a potent cellular 
immune responses43. Rv3615c [Esx-1 substrate protein C (EspC)], encoded outside of RD1, is an antigen that 
is already part of the DIVA skin test prototyope described by Whelan et al.33. The MPB70 and MPB83 antigens 
were reported to be highly specific and sensitive for the detection of M. bovis infection in animals without any 
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cross-reaction with Mycobacterium spp. found in the environment44–46. Lastly, Rv3616c is a CD8 antigen in mice 
with characteristics of the Esx family of bacterial proteins47. It is also strongly recognised by T cells from infected 
cattle48. We therefore chose to delete these genes from BCG Danish.
Construction of modified ΔBcG tK vaccine. All 5 antigen genes were removed using specialized trans-
duction method49 by three sequential deletion steps each using vectors with different antibiotic cassettes for the 
selection of mutants at each stage (Fig. 1b) to make a ΔBCG TK mutant. PCR analysis of the genetic constructs50 
created to make the deletion mutants were all of the expected size (Sup. Fig. 2).
Growth analysis of ΔBcG tK mutants in standard growth medium and in bovine macrophages. 
To confirm that the deletion of the genes did not have any growth defect, we first tested the in vitro growth kinet-
ics of the mutant strain compared to WT BCG in a competition assay. When co-cultured with wild type BCG in 
7H9 media the TK mutant did not show any loss of fitness when compared to WT (Fig. 2a). We next sought to 
determine whether the deletion of BCG antigenic genes influenced the survival of BCG in bovine macrophages. 
PBMC-derived bovine macrophages were infected with the mixture (1:1) of WT BCG and the ΔBCG TK mutant. 
The ΔBCG triple mutant survived in the macrophages as well as WT BCG (Fig. 2b). This confirms that the 
removal of antigens does not alter the in vitro or ex vivo growth characteristics of the ΔBCG TK strain.
Protective efficacy of ΔBcG tK in guinea pigs. The aerosol-infection guinea pig model of human TB 
and bovine TB is commonly used as a screening tool to assess the protective efficacy of vaccines51,52. M. bovis chal-
lenge of guinea pigs has also proven useful to test the potency of vaccines against bovine TB53. Dunkin Hartley 
guinea pigs were randomly divided into four groups. Group 1 and Group 2 were immunised subcutaneously on 
Figure 1. (a) Bean plot of fold changes during in vivo passage in cattle for selected gene groups and (b) 
Schematic representation of creating △BCG TK. (a) Black lines show the medians; white lines represent 
individual antigenic genes; polygons represent the estimated density of the data. The grey regions is a density 
plot of the data’s distribution. Values are normalised to the median value of the ‘All gene’ group. The plots were 
created with BoxPlotR (Spitzer, Wildenhain et al. 2014) (b) △BCG TK was created by sequential gene knock 
out using specialized Transduction method (Bardov et al. 2002). The Phagemid used was Phae159 and the 
cosmids used were p0004S, pYUB854 and pANEE001 to create △BCG 3043, ΔBCG3043/BCG2897/BCG2895 
(Double knock out) and ΔBCG3043/2897/2895/3679/3680 (Triple knock out) respectively.
Figure 2. Competitive survival of selected mutants in vitro and ex vivo conditions. Competitive in vitro survival 
of selected mutants in (a) media and (b) bovine macrophages. Approximately equal number of WT BCG 
Danish and BCG knockout were mixed and used to inoculate media, infect PBMC derived bovine macrophages. 
Inoculants and recovered BCG were enumerated on selective media. Error bars represent standard errors.
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the nape with ΔBCG TK (5 × 104 cfu) and the wild-type BCG respectively. Group 3 and Group 4 were unvacci-
nated controls. Protective immunity was assessed as the ability to reduce disease progression following challenge 
at 42 days post-vaccination (Fig. 3a) with virulent M. bovis (10–20 cfu delivered by aerosol). Disease progression 
was assessed by weight loss, a sensitive indicator of TB in the guinea pig model. Disease burden was quantified by 
measurement of viable M. bovis in lungs and spleens.
The uninfected controls (Group 4) together with all animals immunized with either ΔBCG TK or wild-type 
BCG gained weight normally after challenge (Fig. 3b). Indeed, there were no significant differences in weight gain 
between these two groups. After 21 days post-infection, however, non-immunized, infected animals (Group 3) 
exhibited a substantial weight loss and were euthanised at a pre-defined humane end-point; whilst the weight of 
vaccinated guinea pigs continued to increase steadily (Fig. 3b).
Although this study was not powered to measure survival, the notable difference between disease progres-
sion in vaccinated and unvaccinated animals permitted an analysis of survival (based upon time to humane 
end-point). The Kaplan Meier plot (Fig. 3c) shows that the vaccinated and challenged guinea pigs all survived 
until the end of the 4-week post-infection observation period, whereas all of the unvaccinated-challenged group 
had been euthanised by this time. In addition, none of the animals vaccinated with either wild-type or ΔBCG 
strains showed any pathological signs of clinical disease thus confirming the protective efficacies of the strain.
To assess the capacity of the recombinant vaccine ΔBCG TK to restrict the growth of M. bovis in tissues of 
challenged guinea pigs, the number of viable bacteria (colony forming units, cfu) in the lung, the primary site 
of infection, and spleen, a major site of bacterial dissemination was quantified at necropsy. The cfu data from 
lungs (Fig. 4a) and spleens (Fig. 4b) of challenged animals showed statistically significantly lower cfu burden in 
the lungs (p < 0.001) and spleens (p = 0.0004) of animals vaccinated with either vaccine compared to unvacci-
nated controls. The reductions in bacterial burden in either organ imparted by vaccination with wild-type BCG 
and ΔBCG TK was indistinguishable (Fig. 4). Together with the data demonstrating prevention of disease pro-
gression, these data on reduced bacterial burden in lungs and spleens following vaccination with either vaccine 
demonstrates that the deletion of the target genes from ΔBCG TK has not reduced its protective efficacy.
Skin test immune response against extended DiVA antigens in guinea pigs. To test whether the 
antigens deleted from ΔBCG TK could induce skin test responses in M. bovis infected guinea pigs, but not in vac-
cinated animals prior to infection, orthologs of the genes deleted from ΔBCG TK: Rv3020c (BCG3043), MPB70 
(BCG2897), MPB83 (BCG2895), Rv3615c were prepared as three different fusion proteins (ESAT-6-CFP-10, 
MPB70-MPB83, Rv3615c-Rv3020c). These were tested alone, or in combination, as synthetic antigen cocktails.
Figure 3. Comparative analysis of body weight and survival ability of ΔBCG TK vaccinated Guinea pigs 
after M. bovis challenge. (a) Schematic representation of study schedule (b) Group mean body weight profiles 
recorded for each group of guinea pigs during the vaccination and challenge phase of the study. Solid red 
vertical bar on x-axis indicates the time point of vaccination and dashed-black vertical bar on x-axis indicates 
time point of challenge with M. bovis. (c) Survival data of unvaccinated and vaccinated (WT BCG, ΔBCG TK) 
guinea pigs up on M. bovis infection.
5Scientific RepoRtS |         (2019) 9:17791  | https://doi.org/10.1038/s41598-019-54108-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Groups of guinea pigs were vaccinated as above with either WT BCG, or ΔBCG TK, or left unvaccinated 
controls, and subsequently challenged with M. bovis. Skin tests were performed on all animals post-vaccination to 
determine specificities, and also performed again post-infection to determine the sensitivities of the test reagents. 
The following antigen preparations were injected in a Latin Square arrangement54 in the sites shown in Fig. 5A: 
PPD-B, fusion proteins of ESAT6-CFP10, MPB70 and MPB83, Rv3615c and Rv3020c. A cocktail of all of these 
three fusion proteins (Triple antigen cocktail) was also tested. The site of injections on both sides of guinea pig’s 
trunk was marked “a, b, c” and “d, e, f (Fig. 5A) and the skin-testing injection regimes were showed in Sup. Table 2.
The groups of animals vaccinated with WT BCG or ΔBCG TK gave no skin reactions with any of the DIVA 
antigen cocktails either 24 h or 48 h post vaccination before challenge with M. bovis. As expected, injection of the 
standard PPD-B skin test reagent gave rise to reactions in both groups of vaccinated guinea pigs, Unvaccinated 
animals did not respond to either the DIVA cocktails or to PPD-B (Fig. 5B,C).
Following M. bovis challenge of these animals, both vaccine groups, as well as the unvaccinated control group, 
showed consistently positive responses to PPD-B with no significant difference in response between the vacci-
nated and unvaccinated animals (Fig. 5D,E). Challenged animals also reacted to the DIVA antigen cocktails, par-
ticularly against the triple fusion protein cocktail injection (MPB70-MPB83, ESAT-6-CFP10 and Rv3615-Rv3020) 
at the 24 h and 48 h measuring time point (Fig. 5D,E). The response to the MPB70/83 DIVA antigen was how-
ever not consistently observed in all animals. Unvaccinated animals showed response to PPD-B and the antigen 
cocktails only after M.bovis challenge. Only 24 h skin-test reactions are shown for animals in this group as they 
had reached the humane end point. Importantly, the antigen cocktails distinguished between BCG and M. bovis 
exposure with skin test reactions occurring only in challenged animals irrespective of their immunization status 
(Sup. Fig. 3).
Discussion
Bovine TB is a serious animal health problem55 and is one of the biggest challenges facing the cattle farming 
industry today56. It has been estimated that >50 million cattle are infected worldwide, costing an estimated US$3 
billion annually57. Even though vaccination with M. bovis BCG showed widely diverging efficacies in cattle and 
humans58–60, it is still the only realistic vaccine candidate with potential benefits in reducing prevalence and spread 
of bovine TB in the cattle population40,57,61 and also reduce the severity of a herd breakdown20,22. The differential 
diagnostic tests will be required in countries where the test and slaughter control strategies are in operation62,63, 
particularly when vaccination involves BCG that will compromise the specificity of standard tuberculin-based 
diagnostic tools64. In order to control the spread of tuberculosis, effective vaccination and accurate early diagnosis 
of the disease are critical. Development of new and improved cattle vaccines, and associated diagnostic reagents, 
could contribute to improved disease control65.
This study is the first step in a novel strategy to engineer a diagnostically compatible BCG vaccine that has 
similar protective efficacy to the current commercially available BCG vaccines. We constructed a ΔBCG TK 
strain that gave indistinguishable protection against BTB challenge as WT BCG. We developed a compatible 
extended DIVA skin test that proved to be specific in not provoking skin reactions in vaccinated guinea pigs 
before challenge but provoking reactions post-challenge. The test, although specific, was not as sensitive as PPD-B 
in the Guinea pig model. Adding additional antigens in a cocktail of 6 antigens, including the prototype DIVA 
antigens ESAT-6, CFP-10 and Rv361566, alongside our triple antigen proteins (MPB70, MPB83 and Rv3020c) 
Figure 4. Protective efficacy of ΔBCG TK vaccination in Guinea pigs upon M. bovis challenge. (a) The 
bacterial load in the lungs of WT BCG (P = 0.0021) and ΔBCG TK (P = 0.0006) vaccinated guinea pigs is 
significantly low compared to the with the unvaccinated control group. (b) The bacterial load in spleen of WT 
BCG (P = 0.0015) and ΔBCG TK (P = 0.0006) vaccinated guinea pigs is significantly low compared to the 
unvaccinated control group. Values for each individual are shown and the horizontal bar denotes the mean for 
each group. *P = ≤ 0.05, P = ≤ 0.01, ***P = ≤ 0.001.
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led to significant increases in skin responses in all groups post-challenge whilst retaining the absence of skin test 
responses post-BCG vaccination prior to challenge.
We note that, as expected, the synthetic antigen cocktail did not provoke a reaction in guinea pigs inoculated 
with the ΔBCG TK strain, but somewhat surprisingly neither did guinea pigs inoculated with WT BCG, which 
still contains the antigens present in the antigen cocktail. This outcome is likely because the guinea pig study was 
not powered sufficiently to demonstrate the relatively small, but economically highly significant, immunoreactiv-
ity to these antigens in animals vaccinated with WT BCG. In support of this interpretation, addition of just one of 
these antigens, Rv3020c, to the standard DIVA cocktail of ESAT-6, CFP-10 and Rv3615c, reduced the specificity 
of the skin test in BCG vaccinated calves from 100% to 96% (100% specificity of ESAT-6, CFP-10, Rv3615c combi-
nation in BCG vaccinated calves in 187 tested animals vs 96% specificity ESAT-6, CFP-10, Rv3615c plus Rv3020c 
in 125 tested animals) (Jones and Vordermeier, unpublished observations). Although this may appear to be a rela-
tively minor reduction in specificity, the economic and societal impact of a 4% false discovery rate when its conse-
quence may be the culling of healthy animals is likely to prevent implementation of such a test, particularly when 
Figure 5. Pre and post-challenge skin test reaction in ΔBCG TK vaccinated guinea pigs. (A) Diagram to show 
the injection layout on animal. At least 2.5 cm between each inoculation of antigen preparations were injected 
on the same flank in a Latin Square arrangement54. The site of injections on both sides of guinea pig’s trunk was 
marked “a, b, c” and “d, e, f ”. (B,C) Pre-challenge skin test: The group mean size of the diameter of erythema 
at 24 (B) and at 48 hours (C) after injection. (D,E) Post-challenge skin test: the mean size of the diameter of 
erythema at 24 (D) and 48 (E) hours after injection. The red line denotes the minimum skin test response (STR) 
threshold (2 mm) for DIVA antigens to consider it as positive. The x-axis denotes the vaccine group. The error 
bars indicate standard deviation for each vaccine group.
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compared to the false-discovery rate of the standard comparative tuberculin test with of 0.02%67. Demonstrating 
a 4% false-positivity with WT BCG and loss of this false-positivity with the ΔBCG TK, advanced DIVA test 
combination would have required large number of guinea pigs and was beyond the scope of this project. Further, 
larger studies, preferentially in the cattle as target host, will be required to demonstrate this aspect of our strategy.
In summary, in this study we demonstrate, for the first time, a new strategy for engineering a live bacterial 
vaccine that has been rationally-designed to optimize both protection and diagnostic compatibility. The DIVA 
cocktail described here is specific and is not affected by vaccination. Although further experiments are needed to 
confirm protective efficacy and diagnostic efficacy in the bovine host, the development of combination of effective 
vaccine and skin test regents could transform bovine TB control programmes worldwide. Similar strategies may 
also be of value for control of human TB, and perhaps other infectious diseases.
Materials and Methods
BcG culture preparation. M. bovis BCG Danish 1331 (Staten’s Serum Institute, batch 111013B) was grown 
on Middlebrook 7H11 solid media or in Middlebrook 7H9 supplemented with 0.2% glycerol, 0.05% Tween-80 
and 10% OADC at 37 °C shaking at 150 rpm in an orbital shaker37. When selection was required antibiotics were 
used at 50 µg ml−1 for apramycin, 50 µg ml−1 for hygromycin and 25 µg ml−1 for zeocin.
construction of the recombinant cosmids containing allelic exchange substrates (AeSs). Cosmid 
pANE001 zeomycin (Sup. Fig. 1) was derived from pYUB854 (Hyg). The original pYUB854 cosmid was modified 
by replacing the hygromycin resistance cassette with zeomycin cassettes. An inverse PCR of pYUB854 with primers 
designed to amplify plasmid backbone less the hygromycin cassette and add Nde1 and Mfe1 restriction ends37. The 
zeomycin cassettes were amplified from pNCMTB plasmid and Nde1 and Mfe1 restriction sites added to the ends37. The 
antibiotic cassette was then cloned into pYUB854, and confirmed by Sanger sequencing. The modified res–MfeI-zeo–
NdeI-res gene cassette flanked by multiple cloning sites (MCSs) was thus created.
construction of BcG null mutants. Mutants were generated sequentially using the mycobacteriophage-based 
method of specialized transduction37,49, and cosmids pANE001 or p0004S. Upstream (LF) and downstream (RF) 
sequences flanking the genes to be mutated were PCR amplified from BCG Danish genomic DNA using Qiagen High 
Fidelity Taq polymerase according to manufacturer’s instructions, cloned into the appropriate cosmids and confirmed 
by Sanger sequencing to generate the knock-out plasmids p0004S3043 (Apra), pANE3679/80 (Zeo) and pYUB2897/95 
(Hyg). Primer sequences used in this study are listed in Sup. Table 4.
Confirmation of mutant construction. As described in the earlier publication37, knockout genotypes 
were confirmed by PCR using primers outside the upstream and downstream flanking regions both alone, and in 
combination with antibiotic cassette specific primers (Sup. Table 4), such that PCR products would be obtained 
only if the antibiotic cassette was inserted in the required genomic location50.
Growth analysis of BcG strains. BCG wild-type and ΔBCG TK mutant were grown to mid-log phase 
(OD 0.8). The cells were pelleted down and washed twice with PBS, then resuspended in 7H9 medium. This 
resuspended bacterium was used to inoculate fresh to a starting OD of 0.05. Growth was measured by taking OD 
readings. All experiments were performed in triplicate.
In vitro competition assays. A mix of strains containing approximately equal amounts of the ΔBCG TK 
mutant and WT BCG Danish were inoculated into broth and cultured for 14 days. At selected time points the 
numbers of each mutant were determined by serially diluting onto selective media. Numbers of WT BCG were 
estimated by subtracting the antibiotic resistant colony numbers from counts from plates without antibiotics37. 
The assays were repeated three times.
Bovine Macrophage preparations and infections. Peripheral blood mononuclear cells (PBMCs) 
obtained from the heparin-anticoagulated blood collected from the adult cows. The PBMCs isolated using 
Ficoll-Histopaque density gradient centrifugation. Monocytes from the pool of PBMCs were selected using CD14 
MicroBeads (Miltenyi Biotec). The monocytes were differentiated into macrophages in 24 well plates containing 
complete RPMI supplemented with 1% sodium pyruvate, 1% penicillin/streptomycin and 20 ng ml-1 macrophage 
colony-stimulating factor (Miltenyi Biotec)37. Fresh medium was added on day 3 and infection on day 6 at a MOI 
of 1 with a mixed BCG culture containing approximately equal amounts of WT BCG and ΔBCG TK mutant. 
Control macrophages were incubated with culture medium only. After 4 h, the infected cells were washed three 
times with PBS. The intracellular bacilli were harvested by lysing the cells with 0.1% Triton X-100 at different time 
points. The mixed culture used for infection, and harvested intracellular bacilli were enumerated as described 
previously37. The assays were repeated three times.
cloning and expression of recombinant proteins. The fusion gene construct (GenScript, USA) of cod-
ing sequences of ESAT-6 and CFP-10, and of Rv3615c and Rv3020 of M. tuberculosis H37Rv were synthesized. 
These gene constructs were then cloned into prokaryotic expression vector pET28a (Novagen) and transformed 
into E. coli BL21 DE3 cells (Invitrogen). The protein expression was induced with 1 mM IPTG overnight at 25 °C. 
The His6 tagged ESAT-6::CFP10 and Rv3615c::Rv3020 fusion proteins were purified from the soluble fraction of 
the bacterial lysate using Ni–NTA agarose (immobilized metal affinity chromatography)68. The pooled protein 
fractions were dialyzed against PBS (pH 7.4) and SDS-PAGE was used to assess the purity of the protein. The 
protein was detected in a Western blot using anti-His6 antibody and the LPS from recombinant fusion proteins 
were removed using Triton X-100 as per the procedure68,69.
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Guinea pig experiments. The Guinea pig experiments were conducted according to the United Kingdom Home 
Office Legislation for animal experimentation and approved by a local ethical committee at Public Health England 
(Porton Down, United Kingdom). Dunkin Hartley guinea pigs free from pathogen-specific infection were randomly 
assigned to vaccine groups and identified using subcutaneously implanted microchips (Plexx, the Netherlands) to ena-
ble blinding of the analyses wherever possible70. Group sizes were determined by statistical power calculations (Minitab, 
version 16) performed using previous data (SD, approximately 0.5) to reliably detect a difference of 1.0 log10 in the 
median number of colony-forming units (cfu) per millilitre70. The guinea pigs were housed in groups of up to eight 
during vaccination and in pairs post-challenge. Animals were monitored daily for behavioural changes.
The 32 animals were divided into 4 groups (n = 8). Groups 1 and 2 were vaccinated subcutaneously on the nape 
with 5 × 104 cfu of either ΔBCG TK (Group 1) or wild type BCG (Group 2) at day 0. Groups 3 and 4 remained 
unvaccinated. All groups received the pre-challenge skin tests at 34 days post-vaccination. Skin test responses (STR) 
were measured at 24- and 48-hours following inoculation with the antigens. Groups 1, 2 and 3 were challenged with 
M. bovis (AF2122/97) at 42 days (6 weeks) post-vaccination and received a post-challenge skin test before the sched-
uled cull and necropsy at 70 days (4 weeks post-challenge). Group 4 was not challenged as this was a control group to 
test for non-specific skin test responses. Guinea pigs in groups 1–3 were challenged by the aerosol delivery with a tar-
get estimated dose of 10–20 cfu of M. bovis using a contained Henderson apparatus in conjunction with an AeroMP 
control unit71–73. Fine particle aerosols of M. bovis, with a mean diameter of 2μm, were generated in a Collison 
nebulizer and delivered directly to the snout of each animal. The AeroMP is a platform system designed to manage 
the aerosol generation, characterization and sampling processes via a dashboard software laptop system. Throughout 
the study, the body weight of each animal was measured and recorded at least weekly. The frequency of checks was 
increased on appearance of any clinical signs or weight loss. The humane endpoint was reached when 20% loss of 
maximal body weight was recorded and/or observation of defined clinical signs such as laboured breathing.
The determination of bacterial load was scheduled at 4 weeks post-challenge. Guinea pigs from each group 
were killed and the lungs and spleens were aseptically removed and stored at −20 °C on the day of necropsy until 
they were processed in a single batch. On the day of tissue processing, each tissue was homogenized in 10 ml 
(lung) or 5 ml (spleen) sterile phosphate buffered saline (PBS). Each tissue homogenate was serially diluted in 
sterile PBS and 100 μl of each dilution plated, in duplicate onto Middlebrook 7H11 + OADC + pyruvate selective 
agar. Following incubation, colonies were enumerated to determine the colony forming units (cfu).
Skin testing. The skin testing was performed 34 days post-vaccination prior to M. bovis challenge 
(pre-challenge skin test) and at 62 days post-vaccination around 4 weeks after M. bovis challenge (post-challenge 
skin tests). All guinea pigs, regardless of vaccination and challenge status were given PPD-B (Group A) and four 
specific DIVA skin test antigen preparations (Group B-E) at six separate injection sites in a Latin square forma-
tion. A diagram of the six sites for each animal (three sites on each flank) is shown in Fig. 5A. The details of the 
group and skin test antigen are given in Sup. Table 1.
Each antigen cocktail was prepared prior to delivery. 100 μl of each antigen preparation (2 μg of PPD-B or 
1 μg of antigen cocktail preparation) was given to the appropriate site by the intradermal route. Each guinea pig 
received each of the five types of antigen preparation and a repeat of one other (on opposite flank) as described 
in Sup. Table 2. The rationale to test one preparation on both flanks of each animal was to determine whether the 
flank side (left or right) influenced the magnitude of the inflammatory response. We didn’t observe any significant 
difference in the magnitude of the skin test response when the same test was given in different locations or on 
either flank which nullify the influence of the position or flank of the skin test location on the magnitude of the 
inflammatory response (Sup. Table 3).
Skin test responses were measured at 24 h and 48 h following antigen inoculation. As we expected, the skin 
test reaction to recombinant proteins were lower than to PPD. Based on the observations in cattle by33 we defined 
cut-off values for positivity for the recombinant proteins at both time points at >2 mm, and >4 mm for PPD. 
The size of the individual erythema reactions (if present) was measured in millimetres (mm) and the average of 
these values was used for analysis. Skin test data were initially analysed using an ANOVA general linear model 
(Latin square) statistical analysis. Group comparisons of the magnitude of skin test were performed using the 
non-parametric Mann-Whitney test (Minitab software version 16). A test for normality was applied to the bac-
terial load data and the data from each vaccine group were compared and ranked using the non-parametric 
Mann-Whitney test (Minitab software version 16).
ethics approval and consent to participate. All animal experimentation was carried out within a pro-
ject license granted by the United Kingdom Home Office Legislation for animal experimentation and approved 
by a local ethical committee at Public Health England (Porton Down, United Kingdom).
Data availability
Illumina and MiSeq sequence data are being submitted to the SRA database under submission SUB4615409.
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